Targeting SPATS2 in lung adenocarcinoma: implications for prognosis and immune-based therapy
SPATS2 is a potential prognostic biomarker and therapeutic target in LUAD. Its role in tumor progression, immune remodeling, and mitochondrial function warrants further investigation in personalized therapy development.
Authors
- Jie Shang (ORCID: https://orcid.org/0000-0002-4962-2607)
- Fangtao Yan
- Jian Shen (ORCID: https://orcid.org/0000-0002-9009-6151)
- Mao-rong Teng
- Xiaohua Sun (ORCID: https://orcid.org/0000-0002-4454-1699)
- Yahui Wang (ORCID: https://orcid.org/0000-0002-4466-0698)
Institutions
- Nantong University (CN)
- Third People's Hospital of Chengdu (CN)
- Taizhou Fourth People's Hospital (CN)
- The Affiliated Taizhou People's Hospital of Nanjing Medical University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-08-08
- DOI
- https://doi.org/10.1007/s12672-025-03179-7
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00